Ovid Therapeutics has been granted a patent for using allosteric modulators and/or gaboxadol to treat epileptic disorders. The patent includes a method for treating status epilepticus by administering ganaxolone through continuous intravenous infusion to maintain a specific plasma concentration. GlobalData’s report on Ovid Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ovid Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ovid Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Ovid Therapeutics's grant share as of April 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of status epilepticus with ganaxolone continuous intravenous infusion

Source: United States Patent and Trademark Office (USPTO). Credit: Ovid Therapeutics Inc

A recently granted patent (Publication Number: US11918563B1) discloses a method for treating status epilepticus in human patients using ganaxolone. The method involves administering ganaxolone as a continuous intravenous infusion to maintain a specific plasma concentration, with the effective amount ranging from less than about 900 ng hr/ml to less than about 650 ng hr/ml. The treatment aims to provide improvement in symptoms for more than 8 hours, 12 hours, or even up to 24 hours, depending on the dosage administered.

Furthermore, the patent outlines specific dosages of ganaxolone to be administered in a 24-hour period, ranging from 1 mg to 2500 mg, with certain embodiments specifying amounts less than about 2000 mg or less than about 1500 mg. Another aspect of the method involves administering an intravenous infusion of ganaxolone ranging from about 500 mg to 1050 mg/day, with variations in dosage such as 625 mg to 700 mg/day or 1025 mg to 1050 mg/day. The treatment method aims to provide improvement in symptoms for an extended period, with specific dosages and concentrations tailored to effectively manage status epilepticus in patients.

To know more about GlobalData’s detailed insights on Ovid Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies